Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK)

被引：150

作者：

Powell, Chelsea E. ^{[1
,4
]}

Gao, Yang ^{[5
,6
]}

Tan, Li ^{[1
,4
]}

Donovan, Katherine A. ^{[1
,4
]}

Nowak, Radoslaw P. ^{[1
,4
]}

Loehr, Amanda ^{[5
,6
]}

Bahcall, Magda ^{[2
]}

Fischer, Eric S. ^{[1
,4
]}

Janne, Pasi A. ^{[2
,3
]}

George, Rani E. ^{[5
,6
]}

Gray, Nathanael S. ^{[1
,4
]}

机构：

[1] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA

[2] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02215 USA

[3] Dana Farber Canc Inst, Belfer Ctr Appl Canc Sci, Boston, MA 02215 USA

[4] Harvard Med Sch, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA

[5] Harvard Med Sch, Dept Pediat Hematol & Oncol, Dana Farber Canc Inst, Boston, MA 02215 USA

[6] Harvard Med Sch, Childrens Hosp Boston, Boston, MA 02215 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2018年 / 61卷 / 09期

基金：

美国国家卫生研究院;

关键词：

CELL LUNG-CANCER; INHIBITOR; RESISTANCE; POTENT;

D O I：

10.1021/acs.jmedchem.7b01655

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

We present the development of the first small molecule degraders that can induce anaplastic lymphoma kinase (ALK) degradation, including in non-small-cell lung cancer (NSCLC), anaplastic large-cell lymphoma (ALCL), and neuroblastoma (NB) cell lines. These degraders were developed through conjugation of known pyrimidine-based ALK inhibitors, TAE684 or LDK378, and the cereblon ligand pomalidomide. We demonstrate that in some cell types degrader potency is compromised by expression of drug transporter ABCB1. In addition, proteomic profiling demonstrated that these compounds also promote the degradation of additional kinases including PTK2 (FAK), Aurora A, FER, and RPS6KA1 (RSK1).

引用

页码：4249 / 4255

页数：7

共 50 条

[21] Anaplastic lymphoma kinase (ALK) inhibitors: a review of design and discovery
Wang, Wen-Chieh
Shiao, Hui-Yi
Lee, Chieh-Chien
Fung, Ka-Shu
Hsieh, Hsing-Pang
MEDCHEMCOMM, 2014, 5 (09) : 1266 - 1279
[22] Detection of anaplastic lymphoma kinase (ALK) by immunostaining varies by antibody
Aoun, P
Greiner, T
Gascoyne, R
Morris, S
Pulford, K
Mason, D
Shiota, M
Chan, W
Weisenburger, D
LABORATORY INVESTIGATION, 1999, 79 (01) : 131A - 131A
[23] Anaplastic lymphoma kinase (ALK) inhibitors for cancer treatment.
Lee, Kvvangho
Kim, Hyoung Rae
Cho, Sung Yun
Jung, Hee Jung
Ha, Jae D.
Yun, Chang-Soo
Kim, Pilho
Park, Chi Hoon
Lee, Chong Ock
MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
[24] Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK)
Zhang, Chengwei
Han, Xiao-Ran
Yang, Xiaobao
Jiang, Biao
Liu, Jing
Xiong, Yue
Jin, Jian
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 151 : 304 - 314
[25] Anaplastic Lymphoma Kinase (ALK) Gene Aberrations in Breast Cancers
Hanna, M. G.
Najfeld, V.
Tripodi, J.
Hanna, I. Y.
Nayak, A.
LABORATORY INVESTIGATION, 2014, 94 : 52A - 52A
[26] Monoclonal antibody targeting of the anaplastic lymphoma kinase (ALK) receptor
Wellstein, A.
LaConti, J. J.
Kim, S. E.
Flachmann, S.
Tassi, E.
Juhl, H.
Riegel, A. T.
EJC SUPPLEMENTS, 2010, 8 (07): : 69 - 69
[27] Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma
Gascoyne, RD
Aoun, P
Wu, D
Chhanabhai, M
Skinnider, BF
Greiner, TC
Morris, SW
Connors, JM
Vose, JM
Viswanatha, DS
Coldman, A
Weisenburger, DD
BLOOD, 1999, 93 (11) : 3913 - 3921
[28] Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma
Merkel, Olaf
Hamacher, Frank
Laimer, Daniela
Sifft, Eveline
Trajanoski, Zlatko
Scheideler, Marcel
Egger, Gerda
Hassler, Melanie R.
Thallinger, Christiane
Schmatz, Ana
Turner, Suzanne D.
Greil, Richard
Kenner, Lukas
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (37) : 16228 - 16233
[29] Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers
Roskoski, Robert, Jr.
PHARMACOLOGICAL RESEARCH, 2017, 117 : 343 - 356
[30] Rare, fulminant presentations of anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma - a case series
Zhang, X. Y.
Eyre, T. A.
Hatton, C.
Hall, G. W.
Collins, G. P.
BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 : 56 - 56

← 1 2 3 4 5 →